212 related articles for article (PubMed ID: 29722658)
1. Management of Borderline Resectable Pancreatic Cancer.
Toesca DAS; Koong AJ; Poultsides GA; Visser BC; Haraldsdottir S; Koong AC; Chang DT
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1155-1174. PubMed ID: 29722658
[TBL] [Abstract][Full Text] [Related]
2. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
Endo Y; Kitago M; Aiura K; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Nakano Y; Itano O; Fukada J; Masugi Y; Kitagawa Y
World J Surg Oncol; 2019 Aug; 17(1):145. PubMed ID: 31420046
[TBL] [Abstract][Full Text] [Related]
4. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Okano K; Suto H; Oshima M; Maeda E; Yamamoto N; Kakinoki K; Kamada H; Masaki T; Takahashi S; Shibata T; Suzuki Y
Ann Surg Oncol; 2017 Sep; 24(9):2777-2784. PubMed ID: 28608121
[TBL] [Abstract][Full Text] [Related]
5. Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
Papalezova KT; Tyler DS; Blazer DG; Clary BM; Czito BG; Hurwitz HI; Uronis HE; Pappas TN; Willett CG; White RR
J Surg Oncol; 2012 Jul; 106(1):111-8. PubMed ID: 22311829
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Therapy: When Should It Be Used for Pancreatic Cancer?
Kelly KN; Macedo FI; Merchant NB
Adv Surg; 2020 Sep; 54():49-68. PubMed ID: 32713439
[No Abstract] [Full Text] [Related]
7. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence.
Müller PC; Frey MC; Ruzza CM; Nickel F; Jost C; Gwerder C; Hackert T; Z'graggen K; Kessler U
Pharmacology; 2021; 106(3-4):143-153. PubMed ID: 32966993
[TBL] [Abstract][Full Text] [Related]
9. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
Kim SS; Nakakura EK; Wang ZJ; Kim GE; Corvera CU; Harris HW; Kirkwood KS; Hirose R; Tempero MA; Ko AH
J Surg Oncol; 2016 Oct; 114(5):587-596. PubMed ID: 27444658
[TBL] [Abstract][Full Text] [Related]
10. Borderline resectable pancreatic cancer and the role of neoadjuvant chemoradiotherapy.
di Sebastiano P; Grottola T; di Mola FF
Updates Surg; 2016 Sep; 68(3):235-239. PubMed ID: 27629483
[TBL] [Abstract][Full Text] [Related]
11. Successful resection after neoadjuvant therapy in pancreatic adenocarcinoma.
Peddi PF; Wang-Gillam A
J Natl Compr Canc Netw; 2012 Nov; 10(11):1330-4. PubMed ID: 23138162
[TBL] [Abstract][Full Text] [Related]
12. Importance of resectability status in neoadjuvant treatment for pancreatic cancer.
Sho M; Akahori T; Tanaka T; Kinoshita S; Nagai M; Tamamoto T; Ohbayashi C; Hasegawa M; Kichikawa K; Nakajima Y
J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):563-70. PubMed ID: 25921623
[TBL] [Abstract][Full Text] [Related]
13. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting.
Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y
J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844
[TBL] [Abstract][Full Text] [Related]
14. Non-metastatic Pancreatic Cancer: Resectable, Borderline Resectable, and Locally Advanced-Definitions of Increasing Importance for the Optimal Delivery of Multimodality Therapy.
Evans DB; George B; Tsai S
Ann Surg Oncol; 2015 Oct; 22(11):3409-13. PubMed ID: 26122369
[No Abstract] [Full Text] [Related]
15. Borderline Resectable and Locally Advanced Pancreatic Cancers: A Review of Definitions, Diagnostics, Strategies for Treatment, and Future Directions.
Khachfe HH; Habib JR; Nassour I; Al Harthi S; Jamali FR
Pancreas; 2021 Oct; 50(9):1243-1249. PubMed ID: 34860806
[TBL] [Abstract][Full Text] [Related]
16. Neoadjuvant chemoradiation with IMRT in resectable and borderline resectable pancreatic cancer.
Kharofa J; Tsai S; Kelly T; Wood C; George B; Ritch P; Wiebe L; Christians K; Evans DB; Erickson B
Radiother Oncol; 2014 Oct; 113(1):41-6. PubMed ID: 25443499
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
[TBL] [Abstract][Full Text] [Related]
19. Current standards and new innovative approaches for treatment of pancreatic cancer.
Conroy T; Bachet JB; Ayav A; Huguet F; Lambert A; Caramella C; Maréchal R; Van Laethem JL; Ducreux M
Eur J Cancer; 2016 Apr; 57():10-22. PubMed ID: 26851397
[TBL] [Abstract][Full Text] [Related]
20. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]